Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy-Reference-Cited by-同舟云学术

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Published:2018-11-01 Issue:11 Volume:4 Page:1543
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Ferrara Roberto¹,Mezquita Laura¹,Texier Matthieu²,Lahmar Jihene¹,Audigier-Valette Clarisse³,Tessonnier Laurent⁴,Mazieres Julien⁵,Zalcman Gerard⁶,Brosseau Solenn⁶,Le Moulec Sylvestre⁷,Leroy Laura⁷,Duchemann Boris⁸,Lefebvre Corentin⁹,Veillon Remi⁹,Westeel Virginie¹⁰,Koscielny Serge²,Champiat Stephane¹¹,Ferté Charles¹¹,Planchard David¹,Remon Jordi¹,Boucher Marie-Eve¹,Gazzah Anas¹¹,Adam Julien¹²,Bria Emilio¹³,Tortora Giampaolo¹⁴,Soria Jean-Charles¹¹,Besse Benjamin¹¹⁵,Caramella Caroline¹⁶

Affiliation:

1. Cancer Medicine Department, Gustave Roussy, Villejuif, France

2. Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif, France

3. Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France

4. Nuclear Medicine Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France

5. Pneumology Department, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France

6. Thoracic Oncology Department, Hôpital Bichat-Claude Bernard, Université Paris-Diderot, Paris, France

7. Medical Oncology Department, Institute Bergonié, Bordeaux, France

8. Medical Oncology Department, Hôpital Avicenne, Bobigny, France

9. Service des Maladies Respiratoires, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

10. Pneumology Department, Centre Hospitalier Universitaire de Besançon, Besançon, France

11. Drug Development Department (DITEP), Gustave Roussy, Villejuif, France

12. Pathology Department, Gustave Roussy, Villejuif, France

13. Medical Oncology, Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy

14. Medical Oncology and University of Verona, Verona, Italy

15. Paris-Sud University, Orsay, France

16. Radiology Department, Gustave Roussy, Villejuif, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference47 articles.

1. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer.;Reck;N Engl J Med,2016

2. OA 17.06 updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS =50%.;Brahmer;J Thorac Oncol,2017

3. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer.;Gandhi;N Engl J Med,2018

4. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.;Hellmann;N Engl J Med,2018

5. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer.;Borghaei;N Engl J Med,2015

Cited by 542 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China;2024-02-06

2. Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy;BMJ Oncology;2024-02

3. Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patients;2024-01-25

4. Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;2024-01-05

5. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma;Journal of Clinical Medicine;2024-01-05